News | March 30, 2026
Sun Pharma to spotlight 14 dermatology studies at 2026 AAD annual meeting
The presentations underscore the company’s deep expertise in dermatology and immunology
The presentations underscore the company’s deep expertise in dermatology and immunology
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The NeuroSakhi initiative aims to close these gaps by strengthening awareness, building patient support networks and improving engagement between healthcare professionals, patients and caregivers across Punjab
Doctors recommended a robotic Strassmann Metroplasty, a reconstructive surgery that joins the two halves of the uterus into a single cavity capable of supporting pregnancy
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
